Related Experiment Video
Updated: Sep 5, 2025
Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
Published on: June 10, 2022
Lipid nanoparticles in the development of mRNA vaccines for COVID-19
Barnabas Wilson1, Kannoth Mukundan Geetha2
1Department of Pharmaceutics, College of Pharmaceutical Sciences, Dayananda Sagar University, Kumaraswamy Layout, Bangalore, Karnataka, 560078, India.
Insights
Lipid nanoparticles (LNPs) are crucial for delivering messenger RNA (mRNA) vaccines. This technology was essential in developing effective COVID-19 vaccines, offering a promising approach for future infectious disease prevention.
Area of Science:
- Biotechnology
- Vaccinology
- Drug Delivery Systems
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, emerged in late 2019, leading to a global health crisis.
- Nucleic acids are increasingly recognized for their therapeutic potential across various diseases.
- Lipid nanoparticles (LNPs) have demonstrated significant promise for the effective delivery of nucleic acids, including mRNA.
Purpose of the Study:
- To explore the application of lipid nanoparticles (LNPs) in the development of mRNA vaccines.
- To highlight the role of LNPs in delivering mRNA for COVID-19 prevention.
Main Methods:
- Review of existing literature on LNP technology and mRNA vaccine development.
- Analysis of the formulation and delivery mechanisms of approved mRNA COVID-19 vaccines.
Main Results:
- LNPs are a key component in the successful development of mRNA vaccines like BNT162b2 and mRNA-1273.
- These LNP-based mRNA vaccines received emergency use authorization for preventing SARS-CoV-2 infection.
Conclusions:
- Lipid nanoparticles represent a vital platform for advancing mRNA vaccine technology.
- The success in COVID-19 vaccine development underscores the potential of LNPs for future therapeutic applications.
Abstract:
Coronavirus disease (COVID-19) was first reported in December 2019, Hubei Province, China. As on 9th December 2021, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has affected 266018810 people worldwide with 5265092 deaths. The outbreak of COVID-19 pandemic has caused severe public health crisis across the world. Nucleic acids have been emerging as potential drugs to treat a variety of diseases. Lipid nanoparticles (LNPs) have great potential to deliver nucleic acids including mRNAs. The two mRNA-based vaccines namely the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have been given emergency use authorization (EUA) by the US-FDA to prevent SARS-CoV-2 caused COVID-19 and the vaccines were developed using LNPs. This article focuses on the potential application of LNPs in the development and delivery of mRNA vaccines for COVID-19.
